Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms AQUARiUS
- Sponsors Janssen Pharmaceutica
- 29 Jun 2017 Planned End Date changed from 28 Feb 2018 to 21 Mar 2018.
- 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Feb 2018.